Zacks: Brokerages Anticipate Sunesis Pharmaceuticals, Inc. (SNSS) Will Post Earnings of -$0.76 Per Share

Equities research analysts expect Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to report earnings of ($0.76) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Sunesis Pharmaceuticals’ earnings. Sunesis Pharmaceuticals posted earnings per share of ($0.72) during the same quarter last year, which would suggest a negative year-over-year growth rate of 5.6%. The business is expected to announce its next quarterly earnings results on Friday, August 4th.

According to Zacks, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($2.10) per share for the current financial year, with EPS estimates ranging from ($2.74) to ($1.45). For the next year, analysts expect that the business will report earnings of ($2.18) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.83) by $0.36. The company had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.57 million. Sunesis Pharmaceuticals had a negative return on equity of 806.43% and a negative net margin of 1,623.12%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.12) earnings per share.

A number of equities analysts have recently weighed in on the stock. Cantor Fitzgerald reissued a “hold” rating and set a $3.00 price target on shares of Sunesis Pharmaceuticals in a research report on Tuesday, May 2nd. Zacks Investment Research raised shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Thursday, May 11th.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Anticipate Sunesis Pharmaceuticals, Inc. (SNSS) Will Post Earnings of -$0.76 Per Share” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/05/20/zacks-brokerages-anticipate-sunesis-pharmaceuticals-inc-snss-will-post-earnings-of-0-76-per-share.html.

Sunesis Pharmaceuticals (NASDAQ:SNSS) traded up 4.50% during mid-day trading on Monday, hitting $3.25. The stock had a trading volume of 102,832 shares. The company’s market cap is $69.75 million. The company has a 50-day moving average price of $3.55 and a 200 day moving average price of $3.88. Sunesis Pharmaceuticals has a 1-year low of $2.76 and a 1-year high of $6.30.

Large investors have recently bought and sold shares of the stock. Morgan Stanley boosted its stake in Sunesis Pharmaceuticals by 768.1% in the first quarter. Morgan Stanley now owns 34,080 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 30,154 shares in the last quarter. TFS Capital LLC bought a new stake in Sunesis Pharmaceuticals during the first quarter valued at approximately $158,000. Geode Capital Management LLC boosted its stake in Sunesis Pharmaceuticals by 9.8% in the first quarter. Geode Capital Management LLC now owns 62,353 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 5,571 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Sunesis Pharmaceuticals by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 110,581 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 16,000 shares in the last quarter. Finally, Neuberger Berman Group LLC boosted its stake in Sunesis Pharmaceuticals by 16.6% in the first quarter. Neuberger Berman Group LLC now owns 140,555 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 20,000 shares in the last quarter. 34.30% of the stock is currently owned by institutional investors and hedge funds.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

12 Month Chart for NASDAQ:SNSS

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply